Copyright © 1998 by the European Society of Cardiology.
Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid
a Coagulation Research, Karolinska Institutet/Karolinska Hospital, Stockholm, Sweden
b Clinical Pharmacology, Karolinska Institutet/Karolinska Hospital, Stockholm, Sweden
accepted April 14, 1998
Aim
To investigate the influence on plasma fibrin gel structure of low and intermediate doses of acetylsalicylic acid in healthy individuals. The influence of acetylsalicylic acid on thrombin formation, fibrinolytic capacity and plasminogen inhibitor-1 in plasma was also investigated.
Methods
Nineteen subjects were treated with 75mg and 11 with 320mg acetylsalicylic acid daily; eight subjects received both doses. Fibrin gel structure was determined by a permeability technique yielding a porosity constant (Ks), and the thromboxane metabolite 11-dehydro-thromboxane B2(TxM) was determined by an ELISA.
Results
Acetylsalicylic acid increased fibrin porosity by 65% at 75mg (P<0·001, n=19), whereas lower increases were found at 320mg (+22%,P<0·05, n=11). One week after withdrawal Kshad essentially returned to baseline (ns). Urinary thromboxane metabolites were suppressed during treatment (–61%,P<0·001 at 75mg, n=19; –46%,P<0·01 at 320mg, n=11). The intra-individual comparison showed similar results (Ks+92%, TxM–62% at 75mg; Ks+5%, TxM–52% at 320mg). Fibrinolytic capacity, plasminogen inhibitor-1 levels and thrombin generation (in platelet-poor citrated plasma) were not influenced.
Conclusion
Low dose acetylsalicylic acid causes the greatest increase in fibrin gel porosity; this may well be of therapeutic importance.The European Society of Cardiology
Key Words: Acetylsalicylic acid (aspirin) • thromboxane metabolites • dosage • controls
f1 Correspondence: Professor Margareta Blombäck, Coagulation Research, Clin Chem Building L2V, Karolinska Hospital, S-171 76 Stockholm, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Undas, K. E. Brummel-Ziedins, and K. G. Mann Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions Blood, March 15, 2007; 109(6): 2285 - 2292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Undas, J. Brozek, M. Jankowski, Z. Siudak, A. Szczeklik, and H. Jakubowski Plasma Homocysteine Affects Fibrin Clot Permeability and Resistance to Lysis in Human Subjects Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1397 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Scott, R. A.S. Ariens, and P. J. Grant Genetic and Environmental Determinants of Fibrin Structure and Function: Relevance to Clinical Disease Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1558 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Mills, R. A.S. Ariens, M. W. Mansfield, and P. J. Grant Altered Fibrin Clot Structure in the Healthy Relatives of Patients With Premature Coronary Artery Disease Circulation, October 8, 2002; 106(15): 1938 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. HE, M. BLOMBACK, G. YOO, R. SINHA, and A. H. HENSCHEN-EDMAN Modified Clotting Properties of Fibrinogen in the Presence of Acetylsalicylic Acid in a Purified System Ann. N.Y. Acad. Sci., June 1, 2001; 936(1): 531 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. HENSCHEN-EDMAN Fibrinogen Non-Inherited Heterogeneity and Its Relationship to Function in Health and Disease Ann. N.Y. Acad. Sci., June 1, 2001; 936(1): 580 - 593. [Abstract] [Full Text] [PDF]
|
|